Search Patents
  • Canine coronavirus vaccine from feline enteric coronavirus
    Patent number: 5750112
    Abstract: This invention provides a vaccine which contains, per dose, an effective immunizing amount of an inactivated feline enteric coronavirus and a suitable carrier. The vaccine of this invention may also contain an adjuvant, an effective immunizing amount of a second inactivated virus and a an effective immunizing amount of an inactivated bacteria. Additionally provided by this invention is a method of immunizing a dog against disease caused by canine coronavirus involving administering to the dog a dose of the vaccine of this invention. The method of this invention may also involve administering one or more additional doses of vaccine to the dog, immunizing the dog against disease caused by a second virus and immunizing the dog against disease caused by a bacteria.
    Type: Grant
    Filed: December 8, 1993
    Date of Patent: May 12, 1998
    Assignee: Solvay Animal Health, Inc.
    Inventor: Michael A. Gill
  • RECOMBINANT NOVEL CORONAVIRUS VACCINE USING REPLICATION-DEFICIENT HUMAN ADENOVIRUS AS VECTOR
    Publication number: 20230022109
    Abstract: Provided is a novel coronavirus vaccine using replication-deficient human type 5 adenovirus as a vector. The vaccine takes the replication-deficient human type 5 adenovirus that is lack of E1 and E3 in a combined mode as a vector, and HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and protective antigenic genes carried are optimized COVID-19 (SARS-CoV-2) S protein genes (Ad5-nCoV). The vaccine has good immunogenicity in both mouse and guinea pig models and can induce the body to produce a strong cellular and humoral immune responses in a short time. Research on the protective effect of hACE2 transgenic mice shows that 14 days after a single Ad5-nCoV immunization, the viral load in lung tissues can be significantly reduced. It shows that the vaccine has a good immune protection effect against COVID-19.
    Type: Application
    Filed: June 15, 2020
    Publication date: January 26, 2023
    Applicants: ACADEMY OF MILITARY MEDICAL SCIENCE, PLA, CANSINO BIOLOGICS INC.
    Inventors: Wei Chen, Shipo Wu, Lihua Hou, Zhe Zhang, Busen Wang, Qiang Guo, Jinlong Zhang, Xiaohong Song, Ling Fu, Jun Zhang, Yi Chen, Zhenghao Zhao, Tao Zhu, Jin Li, Chunlin Xin
  • CORONAVIRUS VACCINE
    Publication number: 20220395570
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: August 9, 2022
    Publication date: December 15, 2022
    Applicant: CureVac AG
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • CORONAVIRUS VACCINE
    Publication number: 20230302122
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: June 1, 2023
    Publication date: September 28, 2023
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • CORONAVIRUS VACCINE
    Publication number: 20220218815
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: November 15, 2021
    Publication date: July 14, 2022
    Applicant: CureVac AG
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • Coronavirus vaccine
    Patent number: 11241493
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: February 8, 2022
    Assignee: CUREVAC AG
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • Coronavirus vaccine
    Patent number: 11964012
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: April 23, 2024
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • CORONAVIRUS VACCINE
    Publication number: 20230293672
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: March 6, 2023
    Publication date: September 21, 2023
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • CORONAVIRUS VACCINE
    Publication number: 20210379181
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: April 15, 2021
    Publication date: December 9, 2021
    Applicant: CureVac AG
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • Coronavirus vaccine
    Patent number: 11576966
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: February 14, 2023
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • CORONAVIRUS VACCINE
    Publication number: 20220193226
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: CureVac AG
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • Coronavirus vaccine
    Patent number: 11883486
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: January 30, 2024
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • Coronavirus vaccine
    Patent number: 11596686
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: March 7, 2023
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • CORONAVIRUS VACCINE
    Publication number: 20230364223
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 16, 2023
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
  • Coronavirus vaccine
    Patent number: 11471525
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: October 18, 2022
    Assignee: CureVac AG
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • ORAL CORONAVIRUS INFECTION VACCINE
    Publication number: 20240091342
    Abstract: Provided is an orally administrable vaccine against a coronavirus infectious disease. A transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium enables the provision of the orally administrable vaccine against a coronavirus infectious disease. The transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium can induce humoral immunity and cellular immunity through oral administration to suppress an increase in severity of pneumonia or the like even after viral infection.
    Type: Application
    Filed: January 25, 2022
    Publication date: March 21, 2024
    Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Kyoto University
    Inventors: Toshiro SHIRAKAWA, Shunpei UENO, Koichi KITAGAWA, Akihiko KONDO, Masanori KAMEOKA, Takane KATAYAMA
  • Coronavirus vaccine
    Patent number: 11964011
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: April 23, 2024
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • VACCINE FOR USE AGAINST CORONAVIRUS AND VARIANTS THEREOF
    Publication number: 20230084012
    Abstract: A novel transgene for use to produce a coronavirus vaccine is provided. The transgene encodes: i) an RNA polymerase promoter; ii) a 5? UTR; iii) a secretory sequence; iv) a coronavirus spike protein component, wherein the spike protein component incorporates a variant sequence at amino acid position 614 of a native spike protein; and v) a 3? UTR and poly A sequence. A vaccine is also provided comprising the transgene or an mRNA transcript thereof.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 16, 2023
    Inventors: Kakon Nag, Juwel Chandra Baray, Maksudur Rahman Khan, Asif Mahmud, Enamul Haq Sarker, Samir Kumar, Jikrul Islam, Rony Roy, Mohammad Mohiuddin, Naznin Sultana
  • NOVEL SALMONELLA-BASED CORONAVIRUS VACCINE
    Publication number: 20230137174
    Abstract: The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the present invention relates to the DNA vaccine for use in the prevention and/or the treatment of coronavirus disease 2019 (COVID-19) or a SARS-CoV-2 infection.
    Type: Application
    Filed: March 31, 2021
    Publication date: May 4, 2023
    Inventors: Heinz LUBENAU, Marc MANSOUR
  • MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES
    Publication number: 20240066114
    Abstract: The present invention is inter alia directed to compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus membrane protein (M), nucleocapsid protein (N), non-structural protein, and/or accessory protein or an immunogenic fragment or immunogenic variant thereof. The composition may additionally comprise at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus spike protein (S). The nucleic acid sequences of the compositions are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The compositions provided herein are for use in treatment or prophylaxis of an infection with at least one Coronavirus, and may therefore be comprised in a vaccine, preferably a multivalent vaccine.
    Type: Application
    Filed: August 30, 2021
    Publication date: February 29, 2024
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Nicole ROTH, Benjamin PETSCH, Wolfgang GROSSE
Narrow Results

Filter by US Classification